Destiny Pharma – Result of General Meeting and Total Voting Rights
Destiny Pharma plc (“Destiny” or the “Company”) Result of General Meeting and
Total Voting Rights
Brighton, United Kingdom ‐ 26 November 2020: Destiny Pharma plc (AIM:DEST) a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections, announces that, at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders on a poll.
Accordingly, the Company has raised total gross proceeds of approximately £10.4 million from the Fundraising and has allotted a total of 15,951,726 New Ordinary Shares. Admission of the 7,783,288 EIS/VCT Placing Shares is expected to occur on 27 November 2020 and the remaining 8,168,438 New Ordinary Shares, comprised of the General Placing Shares, Subscription Shares and Open Offer Shares, are expected to be admitted on 30 November 2020.
Following General Admission on 30 November 2020, the Company’s issued ordinary share capital will comprise 59,816,921 Ordinary Shares, none of which are held in treasury. The above figure of 59,816,921 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA’s Disclosure Guidance and Transparency Rules.
A summary of the votes received for the General Meeting will be made available on the Company’s website at www.destinypharma.com.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 9 November 2020.
Enquiries:
| Destiny Pharma plc | +44 (0) 1273 704 440 |
| Neil Clark (Chief Executive Officer)
Shaun Claydon (Chief Financial Officer and Company Secretary) |
|
| finnCap Limited ‐ Nominated Adviser and Joint Broker | +44 (0) 20 7220 0500 |
| Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance) Alice Lane (ECM) | |
| WG Partners LLP ‐ Joint Broker | +44 (0) 20 3705 9330 |
| Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig | |
| Optimum Strategic Communications | +44 (0) 203 174 1789 |
Mary Clark / Shabnam Bashir / Manel Mateus
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1. | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Neil Clark | |||
| 2. | Reason for the Notification | ||||
| a) | Position/status | Chief Executive Officer | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Destiny Pharma plc | |||
| b) | LEI | 213800O9WH9Z38EHAC95 | |||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the Financial instrument, type of instrument
Identification code |
Ordinary shares of 1 pence each (“Ordinary Shares”)
DEST GB00BDHSP575 |
|||
| b) | Nature of the transaction | Purchase of Ordinary Shares | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| 65 pence | 38,462 | ||||
| d) | Aggregated information: Aggregated volume
Price |
See 4c) above |
|||
| e) | Date of the transaction | 26 November 2020 | |||
| f) | Place of the transaction | London Stock Exchange, AIM Market | |||
| 1. | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Nick Rodgers | |||
| 2. | Reason for the Notification | ||||
| a) | Position/status | Chairman | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Destiny Pharma plc | |||
| b) | LEI | 213800O9WH9Z38EHAC95 | |||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the Financial instrument, type of instrument
Identification code |
Ordinary shares of 1 pence each (“Ordinary Shares”)
DEST GB00BDHSP575 |
|||
| b) | Nature of the transaction | Purchase of Ordinary Shares | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| 65 pence | 38,462 | ||||
| d) | Aggregated information:
Aggregated volume Price |
See 4c) above |
|||
| e) | Date of the transaction | 26 November 2020 | |||
| f) | Place of the transaction | London Stock Exchange, AIM Market | |||
| 1. | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Debra Barker | |||
| 2. | Reason for the Notification | ||||
| a) | Position/status | Non‐Executive Director | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Destiny Pharma plc | |||
| b) | LEI | 213800O9WH9Z38EHAC95 | |||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the Financial instrument, type of instrument
Identification code |
Ordinary shares of 1 pence each (“Ordinary Shares”)
DEST GB00BDHSP575 |
|||
| b) | Nature of the transaction | Purchase of Ordinary Shares | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| 65 pence | 38,461 | ||||
| d) | Aggregated information: Aggregated volume
Price |
See 4c) above |
|||
| e) | Date of the transaction | 26 November 2020 | |||
| f) | Place of the transaction | London Stock Exchange, AIM Market | |||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END